Filter Results:
(1,049)
Show Results For
- All HBS Web
(1,936)
- People (3)
- News (580)
- Research (1,049)
- Events (3)
- Multimedia (19)
- Faculty Publications (561)
Show Results For
- All HBS Web
(1,936)
- People (3)
- News (580)
- Research (1,049)
- Events (3)
- Multimedia (19)
- Faculty Publications (561)
Sort by
- December 2016
- Article
Impact Investing: A Brief History
By: Brian Trelstad
Over the last decade, impact investing has become an increasingly-discussed topic in the realms of both business and public policy. Impact investors are motived by a desire to advance social or environmental goals and an intuition that pursuing two goals at once -... View Details
Trelstad, Brian. "Impact Investing: A Brief History." Capitalism and Society 11, no. 2 (December 2016).
- 14 Feb 2005
- Research & Ideas
Desktop Search and Revenue Streams
The name of the game in Internet search has always been helping users find what they're looking for as quickly as possible, as precisely as possible. The panelists at the 2005 Cyberposium's "Search Visionary" session at Harvard Business School on January 29th... View Details
Keywords: by Julie Jette
- 07 Mar 2018
- Research & Ideas
Electronic Health Records Were Supposed to Cut Medical Costs. They Haven't.
Despite the promise that electronic health records would cut billing costs, savings have yet to materialize, according to a major new study by researchers at Harvard Business School and Duke University. “The theory was that part of... View Details
- 05 Nov 2021
- Op-Ed
How to Tap the Talent Automated HR Platforms Miss
As the global staffing shortage grinds on, corporate recruiters everywhere are relying on their online hiring platforms and automated systems to deliver the candidates they need. Too often, these tools will fail them, sidelining many qualified workers in the process.... View Details
Keywords: by Joseph B. Fuller
- September 2017 (Revised July 2023)
- Case
Adaptive Platform Trials: The Clinical Trial of the Future?
By: Ariel D. Stern and Sarah Mehta
In July 2017, Dr. Brian M. Alexander, president and CEO of the AGILE Research Foundation, was preparing to launch a new type of clinical trial—an adaptive platform trial—to study potential therapies for glioblastoma (GBM), an aggressive form of brain cancer.... View Details
Keywords: Clinical Trials; Cancer; Adaptive Platform Trials; Platform Trials; Adaptive Trials; Glioblastoma; Health; Health Care and Treatment; Health Testing and Trials; Business Strategy; Innovation Strategy; Health Industry; United States
Stern, Ariel D., and Sarah Mehta. "Adaptive Platform Trials: The Clinical Trial of the Future?" Harvard Business School Case 618-025, September 2017. (Revised July 2023.)
- Summer 2024
- Article
The Business Revolution: Economy-Wide Impacts of Artificial Intelligence and Digital Platforms
By: Hanna Halaburda, Jeffrey Prince, D. Daniel Sokol and Feng Zhu
In this essay, we identify several themes of the digital business transformation, with a particular focus on the economy-wide impacts of artificial intelligence and digital platforms. In doing so, we highlight specific industries, beyond just the high-profile “Big... View Details
Halaburda, Hanna, Jeffrey Prince, D. Daniel Sokol, and Feng Zhu. "The Business Revolution: Economy-Wide Impacts of Artificial Intelligence and Digital Platforms." Journal of Economics & Management Strategy 33, no. 2 (Summer 2024): 269–275.
- October 2018
- Case
Accomplice: Scaling Early Stage Finance
By: Ramana Nanda, Raffaella Sadun and Olivia Hull
Accomplice, an early-stage venture capital firm based in Boston, is raising its second fund in November 2017. Since 2009, the firm has followed a seed-led investment model, investing in tech companies at the earliest stages, often when products and business models are... View Details
Keywords: Early Stage Finance; Seed Finance; Scouts; Venture Capital; Business Startups; Private Equity; Investment Portfolio; Organizational Structure; Organizational Change and Adaptation; Partners and Partnerships; Networks; Adaptation; Corporate Strategy; Technology; Financial Services Industry; Massachusetts; Boston; Cambridge; United States
Nanda, Ramana, Raffaella Sadun, and Olivia Hull. "Accomplice: Scaling Early Stage Finance." Harvard Business School Case 719-403, October 2018.
- March 2003
- Case
DigaMem Inc.
DigaMem is a semiconductor firm with a promising new technology, but its CEO faces a difficult financing problem. He is considering issuing a new security: a floorless convertible bond, also known as a "toxic" convertible. View Details
Chacko, George C., Eli Strick, Andrew Kuhlman, and Christopher Smith. "DigaMem Inc." Harvard Business School Case 203-002, March 2003.
- Fall 2012
- Article
The Flattening Firm—Not As Advertised
By: Julie Wulf
For decades, management consultants and the popular business press have urged large firms to flatten their hierarchies. Flattening (or delayering, as it is also known) typically refers to the elimination of layers in a firm's organizational hierarchy and the broadening... View Details
Wulf, Julie. "The Flattening Firm—Not As Advertised." California Management Review 55, no. 1 (Fall 2012): 5–23.
- April 2001 (Revised August 2001)
- Case
Strategic Planning at Sun Life
Describes the firm's strategic planning activities and focuses on the challenge of developing processes that enable the firm to improve the core business as well as processes that foster the creation of promising new business opportunities. View Details
Keywords: Strategic Planning
Roberto, Michael. "Strategic Planning at Sun Life." Harvard Business School Case 301-084, April 2001. (Revised August 2001.)
- August 2013 (Revised July 2014)
- Case
Coffee Wars in India: Café Coffee Day Takes On the Global Brands
By: David B. Yoffie and Tanya Bijlani
Café Coffee Day (CCD) is contemplating how to respond to the entry of Starbucks into the Indian coffee chain market. The case study describes the emergence of CCD as the leading coffee chain in India, with over 1,400 cafes in India. In early 2013, Starbucks, the... View Details
Yoffie, David B., and Tanya Bijlani. "Coffee Wars in India: Café Coffee Day Takes On the Global Brands." Harvard Business School Case 714-409, August 2013. (Revised July 2014.)
- August 2012 (Revised August 2024)
- Module Note
Evaluating the Viability of Innovative Technology-Commercializing Ventures
A guide for how a person who is not an expert in either technology nor business can, nevertheless, exaluate whether two promising innovative medical technologies are technically and/or financially feasible.
Hint: I would not invest in either. View Details
Keywords: Medical Devices and Supplies Industry
Herzlinger, Regina E. "Evaluating the Viability of Innovative Technology-Commercializing Ventures." Harvard Business School Module Note 313-070, August 2012. (Revised August 2024.)
- June 2016
- Case
Alnylam: Building a Biotechnology Powerhouse
By: Kevin Schulman
Alnylam is an early stage biomedical technology focused on commercial development of a novel technology platform, siRNA. This technology offered promise to treat rare genetic disorders that could not be treated with other technologies. Alnlyam's development entailed... View Details
- 09 Apr 2007
- Research & Ideas
Industry Self-Regulation: What’s Working (and What’s Not)?
wages—when their doing so seems like more of a marketing ploy than a substantive effort to address the underlying problems. Very few of these programs require third-party verification. But I suspect that to really deliver on the promise... View Details
Keywords: by Martha Lagace
- August 1998 (Revised July 2002)
- Case
Innovation at 3M Corporation (A)
By: Stefan H. Thomke and Ashok Nimgade
Describes how 3M Corp. introduces and learns a new and innovative methodology called Lead User research to understand future customer and market needs. A team from 3M's Medical-Surgical Markets Division applies the Lead User methodology to the field of surgical... View Details
Keywords: Innovation and Management; Innovation Strategy; Managerial Roles; Marketing Strategy; Demand and Consumers; Market Timing; Product Development; Problems and Challenges; Business Strategy; Medical Devices and Supplies Industry
Thomke, Stefan H., and Ashok Nimgade. "Innovation at 3M Corporation (A)." Harvard Business School Case 699-012, August 1998. (Revised July 2002.)
- Article
Managing the Use and Dissemination of Information about Biomarkers: The Importance of Incentive Structures.
By: Ariel Dora Stern
The use of biomarkers holds great promise for the development of new therapeutics and the acceleration of clinical research. However, biomarkers must be validated—a complex and costly endeavor. Importantly, biomarker validation is meaningfully shaped by economic and... View Details
Stern, Ariel Dora. "Managing the Use and Dissemination of Information about Biomarkers: The Importance of Incentive Structures." Journal of Law, Medicine & Ethics 47, no. 3 (September 2019): 396–397.
- March 2014
- Article
Why China Can't Innovate
By: Regina M. Abrami, William C. Kirby and F. Warren McFarlan
A look at how innovation is happening in China—from the top down, from the bottom up, through acquisition, and through education. Sheds light on the complexities of the issue, highlighting the promise and the problems China faces in its quest to become the world's... View Details
Abrami, Regina M., William C. Kirby, and F. Warren McFarlan. "Why China Can't Innovate." Harvard Business Review 92, no. 3 (March 2014): 107–111.
- 2009
- Book
The Innovator's Prescription: A Disruptive Solution for Health Care
By: Clayton M. Christensen, Jerome H. Grossman M.D. and Jason Hwang M.D.
A groundbreaking prescription for health care reform—from a legendary leader in innovation. Our health care system is in critical condition. Each year, fewer Americans can afford it, fewer businesses can provide it, and fewer government programs can promise it for... View Details
Keywords: Governing Rules, Regulations, and Reforms; Health Care and Treatment; Disruptive Innovation; Health Industry; United States
Christensen, Clayton M., Jerome H. Grossman M.D., and Jason Hwang M.D. The Innovator's Prescription: A Disruptive Solution for Health Care. McGraw-Hill, 2009. (Winner of James A. Hamilton Award Given annually to the author of a management or healthcare book judged outstanding by the American College of Healthcare Executives' Book of the Year Committee presented by American College of Healthcare Executives.)
- September 2016 (Revised November 2017)
- Case
Casper Sleep Inc.: Marketing the 'One Perfect Mattress for Everyone'
By: Robert J. Dolan
“A Warby Parker of mattresses? Somebody is going to do it. Why not us?”
This was the topic of a conversation begun in spring 2013 among Gabe Flateman, Philip Krim, Neil Parikh, and T. Luke Sherwin. The four met as members of a New York City venture accelerator... View Details
Keywords: Mattress; Sleep; Marketing; Business Model; Marketing Channels; Adoption; Sales; Consumer Products Industry
Dolan, Robert J. "Casper Sleep Inc.: Marketing the 'One Perfect Mattress for Everyone'." Harvard Business School Case 517-042, September 2016. (Revised November 2017.)
- March 2021 (Revised August 2021)
- Supplement
Wendell Weeks at Corning Inc. (B): Valor Glass and the COVID-19 Pandemic
By: Ryan Raffaelli and Aldo Sesia
The (B) case offers a detailed account of Wendell Weeks’s innovation strategy at Corning, and how his approach played a critical role in the COVID-19 pandemic. It illustrates the company’s philosophy of making long-term investments in promising new technologies and... View Details
Keywords: Innovation and Invention; Innovation Strategy; Technological Innovation; Disruptive Innovation; Information Technology; Leadership; Health Pandemics; Technology Industry; United States; New York (city, NY)
Raffaelli, Ryan, and Aldo Sesia. "Wendell Weeks at Corning Inc. (B): Valor Glass and the COVID-19 Pandemic." Harvard Business School Supplement 421-078, March 2021. (Revised August 2021.)